JPH0527618B2 - - Google Patents
Info
- Publication number
- JPH0527618B2 JPH0527618B2 JP4246984A JP4246984A JPH0527618B2 JP H0527618 B2 JPH0527618 B2 JP H0527618B2 JP 4246984 A JP4246984 A JP 4246984A JP 4246984 A JP4246984 A JP 4246984A JP H0527618 B2 JPH0527618 B2 JP H0527618B2
- Authority
- JP
- Japan
- Prior art keywords
- urea
- taurine
- amount
- present
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 30
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 29
- 239000004202 carbamide Substances 0.000 claims description 29
- 229960003080 taurine Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- -1 Stearic acid monoglycerol ester Chemical class 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は尿素水溶液配合製剤において長期間尿
素の安定性を保持させる方法に関するものであ
る。
尿素は皮膚の角層の吸湿性を高める作用や、角質
溶解作用があるので、魚鱗癬、老人性乾皮症、ア
トピー性皮膚炎等の疾患用の外用製剤中に配合さ
れたり、保湿効果を高めるために化粧料中に配合
されてきた。また、単純水溶液を利尿剤として内
服する場合もある。
しかし、尿素は水の共存下で徐々に分解するこ
とが知られており、この分解は酸、アルカリの共
存下ではさらに促進される。尿素が分解するとア
ンモニアガスが発生し、アンモニアガスは周知の
通り、強い刺激臭を有するので、大きな欠点とな
つていた。
本発明者らはかかる事情に鑑み鋭意研究の結
果、尿素とともにタウリンを配合したならば、尿
素の分解反応を抑制することができることを見い
出し、本発明を完成した。
すなわち、本発明は、尿素水溶液にタウリンを
配合することを特徴とする尿素の安定化法であ
る。
以下、本発明について詳述する。本発明におい
ては、タウリンの添加量は、配合される尿素の量
あるいは保存される条件、期間などや希望する分
解抑制の度合によつてそれぞれ適量を選ぶことが
できるが、尿素量に対するタウリン量が増すほど
抑制効果は大きくなる。安定性を向上させる目的
で配合されるタウリンの量は、尿素に対して1/10
重量以上、３倍量以下が望ましい。但し、過剰の
タウリンの添加はタウリン自身が変質し、変色、
変臭などを生じるために任意が必要である。また
本発明で用いられる尿素水溶液の濃度は任意であ
る。さらに、尿素水溶液が油相等と乳化されて乳
状製剤の形等になつていても本発明の効果には全
く差し支えない。
尿素の微量の分解を追跡するためにはPH変化を
観察するのが簡便でしかも正確である。すなわ
ち、尿素が分解するとPHが上昇する。以下に尿素
とタウリンを併用した場合の系のPH変化などを示
す。表１は尿素およびタウリンをそれぞれの量、
精製水に溶解し、全量を100とした水溶液のPH値
変化とアンモニア臭の評価結果である。
タウリンを添加しない尿素のみの水溶液の場合
はPH値が上昇し、それに伴つてアンモニア臭が発
生する。しかし本発明のタウリンを添加したもの
についてはPH変化は若干あるものの、かなり低く
おされられアンモニア臭も認められない。
The present invention relates to a method for maintaining the stability of urea for a long period of time in a preparation containing an aqueous urea solution. Urea has the effect of increasing the hygroscopicity of the stratum corneum of the skin and has a keratolytic effect, so it is often incorporated into external preparations for diseases such as ichthyosis, senile xeroderma, and atopic dermatitis, and has a moisturizing effect. It has been incorporated into cosmetics to enhance the skin's appearance. In addition, a simple aqueous solution may be taken orally as a diuretic. However, it is known that urea gradually decomposes in the coexistence of water, and this decomposition is further accelerated in the coexistence of acids and alkalis. When urea decomposes, ammonia gas is generated, and as is well known, ammonia gas has a strong pungent odor, which has been a major drawback. In view of these circumstances, the present inventors conducted intensive research and found that the decomposition reaction of urea can be suppressed by blending taurine with urea, thereby completing the present invention. That is, the present invention is a method for stabilizing urea, which is characterized by incorporating taurine into an aqueous urea solution. The present invention will be explained in detail below. In the present invention, the amount of taurine to be added can be selected depending on the amount of urea to be added, storage conditions, period, etc., and the desired degree of suppression of decomposition, but the amount of taurine relative to the amount of urea is The more the amount increases, the greater the suppressing effect becomes. The amount of taurine added to improve stability is 1/10 that of urea.
It is desirable that the amount is more than 3 times the weight and less than 3 times the amount. However, if excessive taurine is added, the taurine itself will deteriorate, causing discoloration and
Any amount is required to cause off-odor, etc. Further, the concentration of the urea aqueous solution used in the present invention is arbitrary. Further, even if the urea aqueous solution is emulsified with an oil phase or the like to form an emulsion preparation, the effects of the present invention will not be affected at all. In order to track the decomposition of minute amounts of urea, observing PH changes is simple and accurate. That is, when urea decomposes, the pH increases. The following shows the PH changes in the system when urea and taurine are used together. Table 1 shows the respective amounts of urea and taurine,
These are the evaluation results of PH value change and ammonia odor of an aqueous solution dissolved in purified water, with the total amount set as 100. In the case of an aqueous solution containing only urea without the addition of taurine, the pH value increases and an ammonia odor is generated accordingly. However, in the case of the taurine-added product of the present invention, although there is a slight pH change, it is kept considerably low and no ammonia odor is observed.
【表】
次に本発明を実施例および比較例によりさらに
詳細に説明するが、本発明はこれにより限定され
るものではない。
実施例 １
Ａ セタノール 3.0wt％
固形パラフイン 5.0
ワセリン 15.0
流動パラフイン 20.0
ステアリン酸モノグリセリンエステル 2.0
P.O.E（60）ソルビタンセスキオレート 2.0
Ｂ 尿素 1.0
タウリン 3.0
精製水 全体を100とする量
Ａに含まれる成分を混合し70℃に加熱し、同様
に加熱したＢの成分中に加える。乳化処理後冷却
処理を行い、外用尿素配合剤を得た。
比較例 １
実施例１処方でタウリンを添加しない（精製水
で置換）もの。
実施例１および比較例１の試料を40℃にて２ケ
月保存した後、尿素の定量を行つた結果、実施例
１では96〜99％の尿素が残存していたのに対し、
比較例１では80〜85％に減少していた。
実施例 ２
尿 素 10.0wt％
精製糖 2.0
タウリン 3.0
精製水 85.0
各成分を精製水に混合溶解し、内用利尿剤とす
る。
比較例 ２
実施例２処方でタウリンを添加しない（精製水
で置換）もの。
実施例２および比較例２の試料を40℃にて２ケ
月保存したのち、尿素の定量を行つた結果、実施
例２では97〜99％の尿素が残存していたのに対
し、比較例２では76〜83％に減少していた。[Table] Next, the present invention will be explained in more detail with reference to Examples and Comparative Examples, but the present invention is not limited thereto. Example 1 A Setanol 3.0wt% Solid paraffin 5.0 Vaseline 15.0 Liquid paraffin 20.0 Stearic acid monoglycerol ester 2.0 POE (60) sorbitan sesquiolate 2.0 B Urea 1.0 Taurine 3.0 Purified water Amount to make the whole 100 Mix the components contained in A Heat to 70°C and add to similarly heated component B. After the emulsification treatment, a cooling treatment was performed to obtain a urea formulation for external use. Comparative Example 1 Example 1 formulation without adding taurine (substituted with purified water). After storing the samples of Example 1 and Comparative Example 1 for two months at 40°C, urea was quantitatively determined. In contrast to Example 1, 96 to 99% of urea remained.
In Comparative Example 1, it decreased to 80-85%. Example 2 Urea 10.0wt% Refined sugar 2.0 Taurine 3.0 Purified water 85.0 Each component was mixed and dissolved in purified water to prepare an internal diuretic. Comparative Example 2 Example 2 formulation in which taurine was not added (replaced with purified water). After storing the samples of Example 2 and Comparative Example 2 for two months at 40°C, urea was quantitatively determined. As a result, 97 to 99% of urea remained in Example 2, whereas in Comparative Example 2, urea remained. In Japan, it decreased to 76-83%.
Claims (1)
徴とする尿素の安定化法。1. A method for stabilizing urea, which comprises adding taurine to an aqueous urea solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4246984A JPS60185757A (en) | 1984-03-06 | 1984-03-06 | Stabilization of urea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4246984A JPS60185757A (en) | 1984-03-06 | 1984-03-06 | Stabilization of urea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60185757A JPS60185757A (en) | 1985-09-21 |
| JPH0527618B2 true JPH0527618B2 (en) | 1993-04-21 |
Family
ID=12636923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4246984A Granted JPS60185757A (en) | 1984-03-06 | 1984-03-06 | Stabilization of urea |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60185757A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61145109A (en) * | 1984-12-19 | 1986-07-02 | Nakanishi Eiko | Cosmetic |
| FR2782922B1 (en) * | 1998-09-09 | 2002-07-19 | Oreal | COMPOSITION CONTAINING UREA AND ITS USES IN THE COSMETIC AND / OR DERMATOLOGICAL FIELD |
| JP5084089B2 (en) * | 2001-06-14 | 2012-11-28 | 大塚製薬株式会社 | Pharmaceutical composition |
| EP2971068B1 (en) | 2013-03-14 | 2019-11-06 | Siemens Healthcare Diagnostics Inc. | Control of ph in aqueous urea-containing solutions utilizing amino acid-containing compositions |
-
1984
- 1984-03-06 JP JP4246984A patent/JPS60185757A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60185757A (en) | 1985-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0531540B2 (en) | ||
| JPH05509099A (en) | Use of pyrimidine 3-oxide derivatives as anti-hair removal agents and compositions for topical application | |
| JPS6291237A (en) | Novel translucent water-in-oil type emulsion | |
| CA1160954A (en) | Cosmetic moisturizer formulation | |
| JPH11180845A (en) | Urea-containing skin cosmetics | |
| JPH0527618B2 (en) | ||
| JPH07206645A (en) | Hair growth agent and cosmetic for hair of head containing the same | |
| KR19990040578A (en) | Nicotinamide-containing ceramide liquid crystal and cosmetic composition comprising the same | |
| JPS59134772A (en) | Stabilization of urea | |
| JPS6241645B2 (en) | ||
| USRE28781E (en) | Carbohydrate agent of high water retention power, process of making same, and composition containing same | |
| US4362747A (en) | Cosmetic cream pack formulation | |
| JPH0531541B2 (en) | ||
| EP0006741A2 (en) | Self-emulsifying cosmetic base | |
| US3285818A (en) | Hair and skin compositions containing pantethine | |
| JP2589761B2 (en) | Cosmetic additives | |
| JPS6147457A (en) | Method for stabilizing urea | |
| JP4926354B2 (en) | Topical skin preparation | |
| JPS6130509A (en) | Dermal external drug | |
| RU2036640C1 (en) | Ointment for treating diseases associated with disorders of keratinization and disintegrity of skin | |
| JPS6147456A (en) | Method for stabilizing urea | |
| Castro et al. | Carbon tetrachloride activation in liver microsomes from rats induced with 3-methylcholantrene | |
| JPS6220166B2 (en) | ||
| JPH01301612A (en) | Hair growth agent | |
| JPS60185708A (en) | External preparation for skin |